Ascomylactam C Induces an Immunogenic Cell Death Signature via Mitochondria-Associated ER Stress in Lung Cancer and Melanoma
Marine Drugs · 2023
DOI: 10.3390/md21120600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2023. Verfasst von Yun Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Melanoma, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Marine Economy Development Special Project, Natural Science Foundation of Guangdong Province, China.
Abstract (Originalsprache)
Ascomylactam C (AsC) is a new 13-membered-ring macrocyclic alkaloid, which was first isolated and identified in 2019 from the secondary metabolites of the mangrove endophytic fungus Didymella sp. CYSK-4 in the South China Sea. AsC has been found to have a broad-spectrum cytotoxic activity. However, the antitumor effects in vivo and mechanisms of AsC remain unclear. The aim of this study was to describe the effects of AsC on lung cancer and melanoma cells and to explore the antitumor molecular mechanism of AsC. In vitro, we used plate colony formation experiments and demonstrated the ability of AsC to inhibit low-density tumor growth. An Annexin V/PI cell apoptosis detection experiment revealed that AsC induced tumor cell apoptosis. In vivo, AsC suppressed the tumor growth of LLC and B16F10 allograft significantly in mice, and promoted the infiltration of CD4+ T and CD8+ T cells in tumor tissues. Mechanistically, by analyses of Western blotting, immunofluorescence and ELISA analysis, we found that AsC increased ROS formation, induced endoplasmic reticulum (ER) stress, activated the protein kinase RNA-like ER kinase (PERK)/eukaryotic translation initiation factor (eIF2α)/activating transcription factor 4 (ATF4)/C/EBP homologous protein (CHOP) signaling pathway, and induced immunogenic cell death (ICD) of tumor cells. Our results suggest that AsC may be a potentially promising antitumor drug candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
- Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou 510080, China.
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
- Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
- School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou 510006, China.
- Department of Traditional Chinese Medicine, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
ORCID-Profile: Zhigang She, Jie Yuan
Förderung
- Guangdong Marine Economy Development Special Project
- Natural Science Foundation of Guangdong Province, China
Zitieren
APA
Huang, Y., Yan, H., Zhang, B., Zhu, G., Yu, J., Xiao, X., He, W., Chen, Y., Gao, X., She, Z., Li, M., & Yuan, J. (2023). Ascomylactam C Induces an Immunogenic Cell Death Signature via Mitochondria-Associated ER Stress in Lung Cancer and Melanoma. Marine Drugs. https://doi.org/10.3390/md21120600
Vancouver
Huang Y, Yan H, Zhang B, Zhu G, Yu J, Xiao X, et al. Ascomylactam C Induces an Immunogenic Cell Death Signature via Mitochondria-Associated ER Stress in Lung Cancer and Melanoma. Marine Drugs. 2023. doi:10.3390/md21120600
BibTeX
@article{Huang2023,
author = {Huang, Yun and Yan, Hongmei and Zhang, Bingzhi and Zhu, Ge and Yu, Jianchen and Xiao, Xuhan and He, Wenxuan and Chen, Yan and Gao, Xiaoxia and She, Zhigang and Li, Mengfeng and Yuan, Jie},
title = {Ascomylactam C Induces an Immunogenic Cell Death Signature via Mitochondria-Associated ER Stress in Lung Cancer and Melanoma},
journal = {Marine Drugs},
year = {2023},
doi = {10.3390/md21120600}
}
EUVIMED